Almost 50 per cent of India's Rs 2.20-lakh-crore annual revenue of the pharmaceutical industry comes from exports. They are under constant regulatory control in the US and Europe on quality, production procedure, packaging and price. The producers can't grumble. Either they fall in line or they lose their profitable exports. Under pressure, they are forced to produce quality medicines, including injectables, follow production procedures and safety norms and meet the pricing pressure. One wonders why the Indian regulatory authorities are less concerned about the quality of drugs the country's same pharmaceutical firms produce, procedures they follow and massive post-manufacturing expenses (PMEs) they load upon the maximum retail price (MRP) of drugs, including marketing through medical practitioners, private clinics and hospitals. Although India's drug price control authority (DPCA) is doing a good job by periodically cutting down prices of scheduled essential drugs and medical devices such as stents, orthopaedic implants, etc, they seem to have little impact on the pockets of patients as the drug or implant administrators invariably raise prices of other attendant procedures and services, in the absence of any pressure from concerned central and state regulatory authorities.